Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 14, 2002.

Joseph E. Salter,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 02–21082 Filed 8–19–02; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Citizens Advisory Committee on Public Health Service Activities and Research at Department of Energy (DOE) Sites: Savannah River Site Health Effects Subcommittee (SRSHES)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), and the Agency for Toxic Substances and Disease Registry (ATSDR) announce the following meeting.

Name: Citizens Advisory Committee on Public Health Service Activities and Research at Department of Energy (DOE) Sites: Savannah River Site Health Effects Subcommittee (SRSHES).

Times and Dates:
8 a.m.–4:30 p.m., September 5, 2002
8 a.m.–11:45 a.m., September 6, 2002

Place: Crowne Plaza, 130 Shipyard Drive, Hilton Head Island, South Carolina 29928, telephone 843–842–2400, fax 843–842–9972.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

Background: Under a Memorandum of Understanding (MOU) signed in December 1990 with DOE, and replaced by MOUs signed in 1996 and 2000, the Department of Health and Human Services (HHS) was given the responsibility and resources for conducting analytic epidemiologic investigations of residents of communities in the vicinity of DOE facilities, workers at DOE facilities, and other persons potentially exposed to radiation or to potential hazards from non-nuclear energy production use. HHS delegated program responsibility to CDC.

In addition, a memo was signed in October 1990 and renewed in November 1992, 1996, and in 2000, between ATSDR and DOE. The MOU delineates the responsibilities and procedures for ATSDR's public health activities at DOE sites required under sections 104, 105, 107, and 120 of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or ''Superfund''). These activities include health consultations and public health assessments at DOE sites listed on, or proposed for, the Superfund National Priorities List and at sites that are the subject of petitions from the public; and other health-related activities such as epidemiologic studies, health surveillance, exposure and disease registries, health education, substance-specific applied research, emergency response, and preparation of toxicological profiles.

Purpose: This subcommittee is charged with providing advice and recommendations to the Director, CDC, and the Administrator, ATSDR, regarding community concerns pertaining to CDC's and ATSDR's public health activities and research at this DOE site. The purpose of this meeting is to provide a forum for community interaction and to serve as a vehicle for community concerns to be expressed as advice and recommendations to CDC and ATSDR.

Matters to be Discussed: Agenda items include: Savannah River Site (SRS) Monitoring Program and Annual Environmental Report; Georgia Department of Health Monitoring Program at SRS; South Carolina Department of Health Monitoring Program at SRS; and ATSDR/Tritium Health Consult on Potential Tritium Exposures at SRS. Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Phillip Green, Executive Secretary, SRSHES, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, CDC, 1600 Clifton Road, NE (E–39), Atlanta, Georgia 30333, telephone (404) 498–1800, fax (404) 498–1811, e-mail *PGreen@cdc.gov.*

Hearing-impaired persons who will attend the meeting and require the services of a sign language interpreter should contact Phillip Green at least ten (10) working days before the scheduled date of the meeting.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and ATSDR.

Dated: August 14, 2002.

Joseph E. Salter,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 02–21085 Filed 8–19–02; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 02223]

The Effect of Trichomonas vaginalis Infection on Vaginal Virus Loads Among HIV-Infected Women—Tulane University Health Sciences Center; Notice of Award of Funds

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the award of fiscal year (FY) 2002 funds for a grant program, ''The Effect of Trichomonas vaginalis Infection on Vaginal Virus Loads among HIV-Infected Women'' to be performed by Tulane University Health Sciences Center, School of Public Health and Tropical Medicine.

Detection and treatment of Trichomonas vaginalis (T. vaginalis) among HIV-infected women may be an important public health strategy in reducing the spread of HIV infection. This is of profound public health importance, as it would advance medical knowledge in the relationship between T. vaginalis (the most common non-viral STD among HIV-infected women) and vaginal shedding of the HIV virus.

The study may lead to a determination of whether or not the effective treatment of T. vaginalis would result in a reduction in the spread of HIV. This study falls under the public health initiative Human Immunodeficiency Virus (HIV) Prevention.

B. Eligible Applicant

Assistance is provided only to Tulane University Health Sciences Center, School of Public Health and Tropical Medicine. Tulane's application contained an important and unique scientific proposal that was not submitted in response to any existing program announcement, but does fall under the embrace of the Government's public health initiative Human Immunodeficiency Virus (HIV) Prevention. The research team at Tulane has a strong background in conducting similar studies. They are the largest provider of care to women co-infected with HIV and T. vaginalis in the gulf south region. They have the research, clinical, and laboratory expertise needed to conduct such a study. The CDC Division of Sexually Transmitted Disease Prevention (DSTD) performed a thorough review of Tulane's proposal and determined that it would significantly advance the state of medical knowledge, and provide a unique contribution to the understanding of T. vaginalis and HIV infectivity.

C. Funds

Approximately $149,979 is being awarded in FY 2002. The award will begin on or about September 15, 2002, and will be made for a 24-month budget period within a project period of two years.

D. Where To Obtain Additional Information

Business management technical assistance may be obtained from: William J. Ryan, Jr., Grants Management Officer, Procurement and Grants Office,

Centers for Disease Control and Prevention, 2920 Brandywine Road, Room 3000, Atlanta, GA 30341–4146, Telephone number 770–488–2717, e-mail address: *wfr4@cdc.gov.*

For program technical assistance, contact: Emily Koumans, MD, Division of STD Prevention, Centers for Disease Control and Prevention, NCHSTP/DSTD, 10 Corporate Square Blvd, Atlanta, GA 30329, Telephone number 404–639–8870, e-mail address: *svs5@cdc.gov.*

Dated: August 13, 2002.

Sandra R. Manning,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 02–21080 Filed 8–19–02; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

A Public Health Action Plan To Combat Antimicrobial Resistance (Part II: Global Issues): Meeting for Public Comment on Development of Part II of the Action Plan (Global Issues)

The Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and National Institutes of Health (NIH) announce an open meeting concerning antimicrobial resistance.

Name: A Public Health Action Plan To Combat Antimicrobial Resistance (Part II: Global Issues): Meeting for Public Comment on the Development of Part II of the Action Plan (Global Issues).

Time and Date: 8:30 a.m.–3:30 p.m., September 26, 2002.

Place: Manchester Grand Hyatt, Manchester Ballroom A & B, 8120 One Market Place, San Diego, California, 92101, U.S.A. Tel: 619–232–1234; Fax: 619–232–5678.

Status: Open to the public, interested experts who are citizens of the United States or other countries are welcomed and encouraged to attend. Limited only by the space available.

Purpose: To solicit comments to aid in the development of A Public Health Action Plan to Combat Antimicrobial Resistance (Part II: Global Issues). The Action Plan serves as a blueprint for specific actions of U.S. government agencies to address the global problem of antimicrobial resistance.

Matters to be Discussed: The agenda will consist of welcome and introductory comments, focusing on the three areas that comprise Part II of the Action Plan, lasting about 90 minutes. The three focus areas are: Surveillance, Prevention and Control, and Research. Breakout groups will then meet to discuss each focus area for approximately 3 hours. Following lunch, the entire group will reconvene for a concluding plenary session lasting approximately 2 hours.

Comments and suggestions from the public for Federal agencies related to each of the focus areas will be taken under advisement by the Antimicrobial Resistance Interagency Task Force. The agenda does not include development of consensus positions, guidelines, or discussions or endorsement of specific commercial products.

The Action Plan (Part I: Domestic Issues) is available at *http://www.cdc.gov/drugresistance.* The public meeting is sponsored by the CDC, FDA, and NIH in collaboration with eight other Federal agencies and departments involved in developing and writing A Public Health Action Plan to Combat Antimicrobial Resistance (Part II: Global Issues).

Agenda items are subject to change as priorities dictate.

Limited time will be available for oral questions, comments, and suggestions from the public. Depending on the number wishing to comment, a time limit may be imposed. In the interest of time, visual aids will not be permitted, although written material may be submitted for subsequent review by the Task Force. Written comments and suggestions from the public are encouraged and should be received by the contact person or email listed below prior to the opening of the meeting or no later than the end of October 2002.

Persons who anticipate attending the meeting are requested to send written notification to the contact person below by September 23, 2002, including name, organization (if applicable), address, phone, fax, and email address.

Contact Person for More Information: Ms. Vickie Garrett, Antimicrobial Resistance, Office of the Director, NCID, CDC, Mailstop C–12, 1600 Clifton Road, NE., Atlanta, GA 30333; telephone 404–639–2603; fax 404–639–4197; or e-mail *aractionplan@cdc.gov*.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 14, 2002.

Joseph E. Salter,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 02–21083 Filed 8–19–02; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Clinical Laboratory Improvement Advisory Committee (CLIAC): Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Clinical Laboratory Improvement Advisory Committee (CLIAC).

Times and Dates:

8:30 a.m.–5:00 p.m., September 11, 2002.
8:30 a.m.–3:30 p.m., September 12, 2002.

Place: CDC, Koger Center, Williams Building, Conference Rooms 1802 and 1805, 2877 Brandywine Road, Atlanta, Georgia 30341.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: This committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact on medical and laboratory practice of proposed revisions to the standards; and the modification of the standards to accommodate technological advances.

Matters To Be Discussed: The agenda will include updates from CDC, the Food and Drug Administration, and the Centers for Medicare & Medicaid Services; a report on the Coordinating Council for Clinical Laboratory Workforce's April 2002 meeting and subsequent activities; reports from several organizations on healthcare workforce issues; Department of Health and Human Services' bioterrorism preparedness and response activities; a report on the Secretary's Advisory Committee on Genetic Testing May 2002 meeting; genetics testing survey results from the Pacific Northwest Sentinel Network; and an update on plans for the April 2003 Quality Institute.

Agenda items are subject to change as priorities dictate.

Contact Person for Additional Information: Rhonda Whalen, Chief, Laboratory Practice Standards Branch, Division of Laboratory Systems, Public Health Practice Program Office, CDC, 4770 Buford Highway, NE, Mailstop F–11, Atlanta, Georgia 30341–3724, telephone 770/488–8042, fax 770/488–8279.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 14, 2002.

Joseph E. Salter,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 02–21081 Filed 8–19–02; 8:45 am]

BILLING CODE 4163–18–P